Drug Profile
Iofolastat I-123
Alternative Names: 123I-MIP-1072; MIP-1072; TrofexLatest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Georgetown University; Johns Hopkins University
- Developer Progenics Pharmaceuticals
- Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA (IV, Injection)
- 22 Jan 2013 Molecular Insight Pharmaceuticals has been acquired by Progenics Pharmaceuticals